Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation

Deborah Cook1, Adam Deane1, François Lauzier1

  • 1From From the Departments of Medicine (D.C., G.G., W.A., M.M., E.D., J.C.D., J.L.Y.T., B. Rochwerg, T.K.), Health Research Methods, Evidence, and Impact (D.C., N.Z., G.G., D.H.-A., G.R., W.A., M.M., L.H., F.C., J.C.D., B. Rochwerg, F.X., L.T.), and Family Medicine (M.V.), McMaster University, Hamilton, ON, the Department of Medicine, University of British Columbia, Vancouver, BC (B.D.), Population Health and Optimal Health Practice Research Unit, Centre Hospitalier Universitaire de Québec, Université Laval Research Center, Quebec, QC (F. Lauzier), St. Joseph's Healthcare Hamilton Research Institute, Hamilton, ON (D.C., F.C., G.G., L.S., L.T., N.Z.), Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto (J. Marshall, K.B., A. Goffi, M.E.W., R.F., N.K.J.A., S.M.); Queen's University, Kingston, ON (J. Muscedere), the Department of Medicine, Critical Care, University of Ottawa, Ottawa (S.E.), Dalhousie University, Halifax, NS (R.H., O.L.), Niagara Health, St. Catharines, ON (E.D., J.L.Y.T.), Université de Sherbrooke, Sherbrooke, QC (F. Lamontagne, F.D., C.S.A.), Brantford General Hospital, Brantford, ON (B. Reeve), North York General Hospital, Toronto (A. Geagea), the Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB (D.N., K.F.), the University of Manitoba, Winnipeg (G.V.-G., R.Z.), Royal Jubilee Hospital, Victoria, BC (D.O., G.W.), Unity Health Toronto-St. Michael's Hospital, Toronto (K.B., A. Goffi), Vancouver General Hospital, Vancouver, BC (W.H.), Nanaimo Regional General Hospital, Nanaimo, BC (D.F.), the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto (R.F., N.K.J.A.), Western University, London, ON (I.B., T.M.), William Osler Hospital, Brampton, ON (A.B., S.T.), Mount Sinai Hospital, Toronto (S.M.), Cambridge Memorial Hospital, Cambridge, ON (I.M.), Centre Hospitalier de l'Université de Montréal (E.C.) and Hôpital du Sacré-Coeur de Montréal (E.C., Y.A.C.), University of Montreal (D.W.), Montreal, Université Laval, Quebec, QC (P.A.), the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton (O.G.R., V.L.), Meakins-Christie Laboratories and Translational Research in Respiratory Diseases Program, Research Institute of the McGill University Health Centre (A.S.K.), and the Department of Critical Care, McGill University (A.S.K., K.K.), Montreal, the Ottawa Hospital Research Institute, Ottawa (S. Kanji), the Department of Medicine, University of Saskatchewan, and the Department of Critical Care, Saskatchewan Health Authority, Regina (E.S.), Royal Columbia Hospital, New Westminster, BC (S.R.), Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est-de-l'Île-de-Montréal, Hôpital Maisonneuve-Rosemont, Montreal (F.M.), Université Laval, Faculté de Médecine, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (F. Lellouche), the Department of Medicine, Windsor Regional Hospital, Windsor, ON (A.R.), Grand River Hospital, Kitchener, ON (P.H.), St. Joseph's Hospital, Toronto (R.C.), St. John Regional Hospital, St. John, NB (M.T.) - all in Canada; the University of Melbourne, Melbourne, VIC (A.D.); the George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales (M.H., J. Myburgh, S. Knowles, N.H., B.V., D.R., L.B., S.F.) and St. George Hospital (J. Myburgh), Sydney, Royal Melbourne Hospital, Melbourne, VIC (K.M.B.), and the University of Adelaide, Adelaide, SA (M.C., A.P.) - all in Australia; King Abdullah International Medical Research Center and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Y.M.A.); King's College London (M.O.) and School of Public Health, Faculty of Medicine, Imperial College (S.F.), London; Medical Research Institute of New Zealand, Wellington, New Zealand (P.Y.); the Department of Anesthesia, Critical Care Medicine, and Pain Medicine, Kuwait Extracorporeal Life Support Program, Al-Amiri Hospital, Ministry of Health, Kuwait City, Kuwait (A.A.-F.); Pontifical Catholic University, Belo Horizonte, Brazil (G.R.); the University of Nebraska Medical Center, Omaha (D.J.); the Department of Pulmonary and Critical Care Medicine, Maroof International Hospital, Islamabad, Pakistan (M.I.); and Midwestern University, College of Pharmacy, Glendale, AZ (J.F.B.).

Abstract

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
287
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
403
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
375
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
440
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162